Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation and Depletion (2017 - 2025)

Historic Depreciation and Depletion for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $76000.0.

  • Cue Biopharma's Depreciation and Depletion fell 2164.95% to $76000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $365000.0, marking a year-over-year decrease of 1666.67%. This contributed to the annual value of $385000.0 for FY2024, which is 2935.78% down from last year.
  • Latest data reveals that Cue Biopharma reported Depreciation and Depletion of $76000.0 as of Q3 2025, which was down 2164.95% from $97000.0 recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Depreciation and Depletion peaked at $232000.0 during Q3 2021, and registered a low of $76000.0 during Q3 2025.
  • Its 5-year average for Depreciation and Depletion is $153479.7, with a median of $145000.0 in 2023.
  • As far as peak fluctuations go, Cue Biopharma's Depreciation and Depletion skyrocketed by 2307.77% in 2021, and later tumbled by 5283.02% in 2023.
  • Cue Biopharma's Depreciation and Depletion (Quarter) stood at $227114.0 in 2021, then dropped by 11.5% to $201000.0 in 2022, then dropped by 27.86% to $145000.0 in 2023, then crashed by 34.48% to $95000.0 in 2024, then dropped by 20.0% to $76000.0 in 2025.
  • Its Depreciation and Depletion stands at $76000.0 for Q3 2025, versus $97000.0 for Q2 2025 and $97000.0 for Q1 2025.